36 results about "Poliomyelitis Infections" patented technology

The invention provides a medicine for dispelling wind, dehumidifying, dredging channels and activating collaterals, which is composed of the following components in parts by weight: 7-10 parts of kadsura pepper stem, 7-10 parts of the root of kudzu vine, 6-9 parts of caulis sinomenii, 3-5 parts of fevervine, 6-9 parts of caulis spatholobi, 5-8 parts of garden balsam stem, 5-8 parts of drynaria rhizome, 6-9 parts of radix clematidis, 5-8 parts of cortex lycii radicis, 4-7 parts of clove, 13-18 parts of prepared sealwort, 4-7 parts of loranthus parasiticus, 4-7 parts of scorpio, 4-8 parts of stiff silkworm, 6-10 parts of pawpaw, and 13-18 parts of liquorice. A plurality of traditional Chinese medicine are matched rigorously, and therefore, the medicine for dispelling wind, dehumidifying, dredging channels and activating collaterals has the effects of eliminating evil and strengthening the body resistance, also has the effects of complementing the vital qi and improving body disease resistance while eliminating pathogenic factors, and is applied to patients suffering from wind, cold and dampness poliomyelitis, anaesthesia, cervical, scapulohumeral and four-limb ankylosis, dizziness, sleepiness, heavy body, muscle limp, fatigability and most of hemiplegia.

The invention provides a Sabin strain poliomyelitis type I virus monoclonal antibody and application thereof, and belongs to the field of immunology. The preparation method of the Sabin strain poliomyelitis type I virus monoclonal antibody comprises the following steps: carrying out immunization on mice with the Sabin strain poliomyelitis type I virus, mixing the mouse spleen cells with the mouse myeloma cells, screening and generating specific monoclonal antibody hybridoma cell strain resistaing against the Sabin strain poliomyelitis type I virus, and preserving the hybridoma cell strain with a preservation No. of CGMCC No.9231. The monoclonal antibody secreted by the hybridoma cell strain is high in valence, and has a large application prospect in diagnosis and treatment of poliomyelitis type I virus; meanwhile, the antibody can be used for specifically distinguishing poliomyelitis virus type I, type II and type III as well as other multiple enteroviruses to achieve good specificity; the Sabin strain poliomyelitis type I virus monoclonal antibody can be used for preparing an antigen content check kit for the poliomyelitis type I virus, and further used for identification and testing of the poliomyelitis type I virus, so that the Sabin strain poliomyelitis type I virus monoclonal antibody is wide in application prospect.

According to the embodiment, the invention discloses a bone bi-disease Lingxianwan (pills for treating bone bi-disease). The Lingxianwan consists of herba epimedii, rhizoma curcumae longae, frankincense, myrrh, radix paeoniae alba, rhizoma corydalis, radix notoginseng, rhizoma dioscoreae nipponicae, radix aucklandiae, flos carthami, radix curcumae, radix angelicae pubescentis, radix achyranthis bidentatae, radix gentianae macrophyllae, cassia twig, dragon's blood, semen strychni. According to the embodiment, the bone bi-disease Lingxianwan provided by the invention has the following effects: 1, dredging collateral and relieving pain: the Lingxianwan can be used for treating rheumatoid arthritis or contracture and numbness; 2, relieving swelling and eliminating stagnation: the Lingxianwan can be used for treating stasis, swelling and pain caused by trauma as well as swelling and pain caused by ulcer; and the Lingxianwan has a certain curative effect on various cancers; 3, the Lingxianwan is effective on treating sequela of poliomyelitis, protrusion of lumbar intervertebral disc, prosopalgia, rheumatoid arthritis, traumatic injury, blood stasis and pain, wind-cold-wetness type of arthralgia, joint contracture and numbness in whole body, cancer swelling and the like. The Lingxianwan is mainly used for treating throat bi-pain, ulcer swelling and toxin, wandering arthritis and pain,fracture, facial paralysis and myasthenia gravis.

Disclosed are 1,3-Dioxoindene derivatives, pharmaceutically acceptable salts thereof or enantiomers, a preparation method thereof, and a pharmaceutical composition for the prevention or treatment of viral diseases, comprising the same as an active ingredient. The 1,3-Dioxoindene derivatives have excellent inhibitory activity against picornaviruses including coxsackie-, entero-, echo-, Polio-, and rhinoviruses, as well as exhibiting low cytotoxicity, so that they can be useful as an active ingredient of a pharmaceutical composition for the prevention or treatment of viral diseases including poliomyelitis, paralysis, acute hemorrhagic conjunctivitis, viral meningitis, hand-foot-and-mouth disease, vesicular disease, hapatitis A, myositis, myocarditis, pancreatitis, diabetes, epidemic myalgia, encephalitis, cold, herpangina, foot-and-mouth disease, asthma, chronic obstructive pulmonary disease, pneumonia, sinusitis or otitis media.

Disclosed are 1,3-Dioxoindene derivatives, pharmaceutically acceptable salts thereof or enantiomers, a preparation method thereof, and a pharmaceutical composition for the prevention or treatment of viral diseases, comprising the same as an active ingredient. The 1,3-Dioxoindene derivatives have excellent inhibitory activity against picornaviruses including coxsackie-, entero-, echo-, Polio-, and rhinoviruses, as well as exhibiting low cytotoxicity, so that they can be useful as an active ingredient of a pharmaceutical composition for the prevention or treatment of viral diseases including poliomyelitis, paralysis, acute hemorrhagic conjunctivitis, viral meningitis, hand-foot-and-mouth disease, vesicular disease, hepatitis A, myositis, myocarditis, pancreatitis, diabetes, epidemic myalgia, encephalitis, flu, herpangina, foot-and-mouth disease, asthma, chronic obstructive pulmonary disease, pneumonia, sinusitis or otitis media.

Disclosed are indanone derivatives, pharmaceutically acceptable salts thereof or enantiomers, a preparation method thereof, and a pharmaceutical composition for the prevention or treatment of viral diseases, comprising the same as an active ingredient. The indanone derivatives have excellent inhibitory activity against picornaviruses including coxsackie-, entero-, echo-, Polio-, and rhinoviruses, as well as exhibiting low cytotoxicity, so that they can be useful as an active ingredient of a pharmaceutical composition for the prevention or treatment of viral diseases including poliomyelitis, paralysis, acute hemorrhagic conjunctivitis, viral meningitis, hand-foot-and-mouth disease, vesicular disease, hepatitis A, myositis, myocarditis, pancreatitis, diabetes, epidemic myalgia, encephalitis, cold, herpangina, foot-and-mouth disease, asthma, chronic obstructive pulmonary disease, pneumonia, sinusitis or otitis media.

The invention provides a Sabin strain poliomyelitis type I virus monoclonal antibody and application thereof, and belongs to the field of immunology. The preparation method of the Sabin strain poliomyelitis type I virus monoclonal antibody comprises the following steps: carrying out immunization on mice with the Sabin strain poliomyelitis type I virus, mixing the mouse spleen cells with the mouse myeloma cells, screening and generating specific monoclonal antibody hybridoma cell strain resistaing against the Sabin strain poliomyelitis type I virus, and preserving the hybridoma cell strain with a preservation No. of CGMCC No.9231. The monoclonal antibody secreted by the hybridoma cell strain is high in valence, and has a large application prospect in diagnosis and treatment of poliomyelitis type I virus; meanwhile, the antibody can be used for specifically distinguishing poliomyelitis virus type I, type II and type III as well as other multiple enteroviruses to achieve good specificity; the Sabin strain poliomyelitis type I virus monoclonal antibody can be used for preparing an antigen content check kit for the poliomyelitis type I virus, and further used for identification and testing of the poliomyelitis type I virus, so that the Sabin strain poliomyelitis type I virus monoclonal antibody is wide in application prospect.

The invention belongs to the field of traditional Chinese medicines and in particular relates to traditional Chinese medicine powder for treating poliomyelitis and a preparation method thereof. The traditional Chinese medicine powder is prepared from the following raw materials in parts by weight: 10-15 parts of cassia twig, 20-25 parts of processed kusnezoff monkshood root, 10-15 parts of stem of sargentgloryvine, 10-25 parts of herb of Sievers wormwood and 10-20 parts of pinellia tuber. The preparation method comprises the following steps: mixing the raw materials in parts by weight uniformly and then grinding the mixture until the grain size is 100 meshes and heating the powder at 60 DEG C for two hours, thus obtaining the traditional Chinese medicine powder. The traditional Chinese medicine powder is simple in formula and reasonable and effective in component matching, has good treatment effects and has the functions of enhancing the physiques of patients, improving the immunities of the patients and radically curing poliomyelitis.

The invention belongs to the technical field of medicaments and relates to a method for purifying the general flavone resin of hollyhock dried flower which is a Chinese herbal medicament in Uyghur. Extract obtained through the backflow extraction with ethanol and the purification of macroporous resin comprises 50 to 90 weight percent of general flavone, wherein the flavone comprises the following components in percentage by weight: 15.0 to 45.0 percent of quercetin, 5.0 to 20.0 percent of kaempferol, 3.0 to 18 percent of astragaloside and the balance of the other flavonoid components. The general flavone extract of the hollyhock flower of the invention is used for preparing the medicaments for treating cough and asthma, detumescence, poliomyelitis, constipation, hemorrhoids, insomnia and amnesia.